{"id":"W4292641407","doi":"10.1038/s41591-022-01933-w","title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Sanofi Genzyme; EMD Serono; AstraZeneca; Genentech; Amgen; Tizona Therapeutics; Chinese Society of Clinical Oncology; Astellas Pharma; Y-mAbs Therapeutics; Eisai; G1 Therapeutics; Lunit; Puma Biotechnology; Relay Therapeutics; Yuhan; Loxo Oncology; Ribon Therapeutics; Syndax Pharmaceuticals; BeiGene; Hong Kong Cancer Fund; Jounce Therapeutics; Regeneron Pharmaceuticals; Helsinn; Mirati Therapeutics; Mylan; Daiichi Sankyo Europe; Takeda Oncology; Foundation Medicine; GlaxoSmithKline; Vertex Pharmaceuticals; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; Merck KGaA; LEO Pharma; Eli Lilly and Company; Calithera Biosciences; AbbVie; Revolution Medicines; Exelixis; Sanofi; National Cancer Institute; Grifols; F. Hoffmann-La Roche; Roche; PharmaMar; OncoMed Pharmaceutical; Incyte; Pfizer; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Population; Cohort; Biomarker; Randomized controlled trial; Confidence interval; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004336933,0.001487442,0.002000585,0.0002684283,0.0003752711,0.001331235,0.0007913611,0.0015091,0.003741561],"category_scores_gemma":[0.003965987,0.0004129861,0.003320139,0.0003611186,0.0006762707,0.0009055388,0.0004933653,0.00340538,0.0005684461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001349178,"about_ca_system_score_gemma":0.001542704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00216545,"about_ca_topic_score_gemma":0.005514245,"domain_scores_codex":[0.998602,0.0009400093,0.00005558294,0.0001859481,0.00009610559,0.0001203845],"domain_scores_gemma":[0.9976286,0.0007845301,0.0006408805,0.0002538139,0.0001512663,0.0005408699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9788905,0.002253523,0.002504971,0.0003210607,0.00188504,0.00003839968,0.00004413685,0.000581241,0.002122127,0.0001153473,0.001783797,0.009459785],"study_design_scores_gemma":[0.9081813,0.07093498,0.01310744,0.00009841172,0.002482458,0.0001296982,0.00004473283,0.001980968,0.0007144582,0.0005473894,0.001739092,0.00003909735],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858914,0.004182183,0.0005853251,0.001070607,0.0003206343,0.002029365,0.003617304,0.00009283982,0.002210385],"genre_scores_gemma":[0.9864939,0.001525706,0.001192729,0.001715354,0.000326071,0.002505642,0.004049978,0.0000451153,0.002145522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004336933,"threshold_uncertainty_score":0.02293622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01030460958035551,"score_gpt":0.3133534069105685,"score_spread":0.303048797330213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}